Drugs / TIMP-GLIA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03486990 | Jan 2018 → May 2019 | celiac disease | Takeda | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03738475 | Nov 2018 → Jun 2019 | celiac disease | Takeda | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-10-22 | Takeda | Results Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study takeda.com ↗
Results of a randomized, double-blind, placebo-controlled clinical trial to assess the markers of potential efficacy and safety of the investigational medicine in 34 adults with proven celiac disease was presented today as a late-breaking abstract at UEG Week 2019, Barcelona, Spain. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-10-22 | Takeda | Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study takeda.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIMP-GLIA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03738475 ↗ |
| Modality | Protein / enzyme biologic | “gluten protein (gliadin) encapsulated in negatively charged poly(dl-lactide-co-glycolic acid) nanoparticles” PMID 33722583 ↗ Mar 2021 |
| Route | Intravenous | “intravenous infusion” NCT03486990 ↗ |